Which of the following is a known AE of ifosfamide?

Which of the following is a known AE of ifosfamide?

• A. Pulmonary fibrosis
• B. Encephalopathy
• C. Myelosuppression
• D. Nephrotoxicity

Answer: (B)

Ifosfamide is a chemotherapeutic agent that is primarily used in oncology for treating various cancers, including testicular cancer and sarcomas. One notable adverse effect associated with ifosfamide treatment is encephalopathy. This neurological complication can manifest as confusion, delirium, or altered mental status and is thought to be related to the drug’s metabolism. Encephalopathy with ifosfamide is also linked to the accumulation of metabolites, particularly chloracetaldehyde, which may be neurotoxic. The risk of encephalopathy increases with higher doses, and it is essential for healthcare providers to monitor patients closely for these neurological symptoms during treatment. Supportive care, dose adjustment, or the use of prophylactic measures (like administering mesna to reduce urotoxicity) can help manage this adverse effect. Understanding this specific adverse event helps emphasize the importance of careful monitoring and the management of side effects in patients receiving this chemotherapeutic agent.

Ifosfamide is a chemotherapeutic agent that is primarily used in oncology for treating various cancers, including testicular cancer and sarcomas. One notable adverse effect associated with ifosfamide treatment is encephalopathy. This neurological complication can manifest as confusion, delirium, or altered mental status and is thought to be related to the drug’s metabolism.

Encephalopathy with ifosfamide is also linked to the accumulation of metabolites, particularly chloracetaldehyde, which may be neurotoxic. The risk of encephalopathy increases with higher doses, and it is essential for healthcare providers to monitor patients closely for these neurological symptoms during treatment. Supportive care, dose adjustment, or the use of prophylactic measures (like administering mesna to reduce urotoxicity) can help manage this adverse effect.

Understanding this specific adverse event helps emphasize the importance of careful monitoring and the management of side effects in patients receiving this chemotherapeutic agent.